A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care

Thomas E. Serena

doi:10.1117/12.2550307

4 March 2020 A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care

Thomas E. Serena

Author Affiliations +

Proceedings Volume 11223, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020; 112230F (2020) https://doi.org/10.1117/12.2550307
Event: SPIE BiOS, 2020, San Francisco, California, United States

Abstract

The clinical signs and symptoms of infection in acute and chronic wounds are unreliable. Similarly, swab cultures are inaccurate in this population. Tissue biopsies and polymerase chain reaction (PCR) are more accurate but the results require several days to obtain. As a result, the clinician is forced to treat patients empirically. This has led to the overuse of antibiotics and the failure of advanced therapies due to unrecognized infection. To address this problem a point-ofcare diagnostic was developed to identify bacteria in acute and chronic wounds. The MolecuLight procedure (MiX) exposes the wound bed to violet light at 405 nm. Bacterial fluorophores absorb the light. In turn they fluoresce at specific wavelengths: porphyrins (red) and pyoverdines (cyan). The device detects bacteria in the wound bed at a level greater than 104 by measuring the amounts of red and or cyan fluorescence. A robust body of literature has demonstrated that elevated bacterial levels impede wound healing. The MiX can detect elevated bacteria burden in a wound allowing the clinician to address the infection. In addition, the device can guide advanced wound therapies such as antibiofilm agents, negative wound pressure therapy and preparation of the wound bed for grafting.

Conference Presentation

Citation Download Citation

Thomas E. Serena "A paradigm shift in chronic wound assessment: incorporating bacterial fluorescence imaging into standard of care", Proc. SPIE 11223, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020, 112230F (4 March 2020); https://doi.org/10.1117/12.2550307

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available